Stock Track | Arcutis Biotherapeutics Soars 5.15% Intraday on Strong Earnings and Analyst Upgrades

Stock Track04:30

Arcutis Biotherapeutics Inc. (ARQT) saw its stock price soar 5.15% during intraday trading on Thursday.

The significant price movement follows the company's release of strong fourth quarter and full year 2025 financial results. Arcutis reported a swing to profitability with Q4 earnings exceeding analyst estimates, while revenue for the quarter showed an 81.5% year-over-year increase driven by robust demand for its ZORYVE product. The company also raised its full-year 2026 net product revenue guidance.

The positive earnings report prompted multiple analyst firms to raise their price targets on the stock, contributing to the bullish sentiment. Morgan Stanley increased its target to $35 from $32, TD Cowen raised its target to $35 from $30, and H.C. Wainwright lifted its target to $34 from $30, with several firms maintaining their Buy ratings.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1124636542?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-27 04:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1124636542","market":"sg","top_or_hot":-1,"title":"Stock Track | Arcutis Biotherapeutics Soars 5.15% Intraday on Strong Earnings and Analyst Upgrades","media":"Stock Track","content":"<p>Arcutis Biotherapeutics Inc. (ARQT) saw its stock price soar 5.15% during intraday trading on Thursday.</p><p>The significant price movement follows the company's release of strong fourth quarter and full year 2025 financial results. Arcutis reported a swing to profitability with Q4 earnings exceeding analyst estimates, while revenue for the quarter showed an 81.5% year-over-year increase driven by robust demand for its ZORYVE product. The company also raised its full-year 2026 net product revenue guidance.</p><p>The positive earnings report prompted multiple analyst firms to raise their price targets on the stock, contributing to the bullish sentiment. Morgan Stanley increased its target to $35 from $32, TD Cowen raised its target to $35 from $30, and H.C. Wainwright lifted its target to $34 from $30, with several firms maintaining their Buy ratings.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Arcutis Biotherapeutics Soars 5.15% Intraday on Strong Earnings and Analyst Upgrades</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Arcutis Biotherapeutics Soars 5.15% Intraday on Strong Earnings and Analyst Upgrades\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-27 04:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Arcutis Biotherapeutics Inc. (ARQT) saw its stock price soar 5.15% during intraday trading on Thursday.</p><p>The significant price movement follows the company's release of strong fourth quarter and full year 2025 financial results. Arcutis reported a swing to profitability with Q4 earnings exceeding analyst estimates, while revenue for the quarter showed an 81.5% year-over-year increase driven by robust demand for its ZORYVE product. The company also raised its full-year 2026 net product revenue guidance.</p><p>The positive earnings report prompted multiple analyst firms to raise their price targets on the stock, contributing to the bullish sentiment. Morgan Stanley increased its target to $35 from $32, TD Cowen raised its target to $35 from $30, and H.C. Wainwright lifted its target to $34 from $30, with several firms maintaining their Buy ratings.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ARQT","symbol_name":"Arcutis Biotherapeutics Inc.","start_time":0,"source_url":"","article_id":"1124636542","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1124636542","pubTimestamp":1772137859,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Arcutis Biotherapeutics Inc. (ARQT) saw its stock price soar 5.15% during intraday trading on Thursday.The significant price movement follows the company's release of strong fourth quarter and full...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ARQT":"Arcutis Biotherapeutics Inc."},"translate_title":"个股追踪|Arcutis Biotherapeutics盘中大涨5.15%因强劲盈利和分析师上调评级","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARQT":1},"content_text":"Arcutis Biotherapeutics Inc. (ARQT) saw its stock price soar 5.15% during intraday trading on Thursday.The significant price movement follows the company's release of strong fourth quarter and full year 2025 financial results. Arcutis reported a swing to profitability with Q4 earnings exceeding analyst estimates, while revenue for the quarter showed an 81.5% year-over-year increase driven by robust demand for its ZORYVE product. The company also raised its full-year 2026 net product revenue guidance.The positive earnings report prompted multiple analyst firms to raise their price targets on the stock, contributing to the bullish sentiment. Morgan Stanley increased its target to $35 from $32, TD Cowen raised its target to $35 from $30, and H.C. Wainwright lifted its target to $34 from $30, with several firms maintaining their Buy ratings.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1124636542","isCrawlerRequest":true}